Influence of Muscle Mass and Strength on Bone Mineralisation with Consideration of Sclerostin Concentration.
Martyna Patalong-WójcikAnna GolaraKatarzyna ZającAlicja SokołowskaMateusz KozłowskiAleksandra Tołoczko-GrabarekMariola KrzyścinAgnieszka BrodowskaAgnieszka JaniecAleksandra MyszkaAneta Cymbaluk-PłoskaElżbieta Sowińska-PrzepieraPublished in: Biomedicines (2023)
Osteoporosis is a disease characterised by a reduction in bone strength due to increased porosity and impaired mineralisation. In our study, we investigated whether muscle strength and mass exert a significant effect on bone mineral density in young adult women. We also tested whether sclerostin can be used as an indicator in the assessment of bone mineralisation. The study included 111 patients. All patients had their bone mineral density determined in the L1-L4 section of the lumbar spine and in the whole skeleton. The parameters of fat mass (FM), lean body mass (LBM) and visceral fat mass (VF) were also determined. Metabolic activity of osteocytes was assessed by measuring the serum sclerostin concentration. There was a statistically significant association of both hands' muscle strength with all parameters expressing bone mineralisation. A statistically significant relationship was also obtained between BMD L1-L4 and the body mass components (FM, LBM). Sclerostin levels in the study did not differ between groups with normal and reduced bone mineral density. Muscle strength assessment may be a potential exponent of reduced bone mineral density, also used clinically in young adult women. The utility of sclerostin in the clinical assessment of bone mineralisation has not been demonstrated.
Keyphrases
- bone mineral density
- postmenopausal women
- body composition
- end stage renal disease
- young adults
- ejection fraction
- chronic kidney disease
- newly diagnosed
- adipose tissue
- polycystic ovary syndrome
- type diabetes
- peritoneal dialysis
- pregnant women
- mass spectrometry
- climate change
- skeletal muscle
- high resolution
- human health
- patient reported outcomes
- atomic force microscopy